In pathological conditions like inflammation and cancer, HGF is proteolytically activated in the stroma and engages MET signaling [22,23], resulting in the activation of several downstream signaling pathways, including the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB), mammalian target of rapamycin (mTOR), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways, which promote cell migration, proliferation, and survival [24,25]. Here, MTOR is linked to cancer.